Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

Irene Ghobrial
Published: Monday, Dec 29, 2014



Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Antibodies offer limited toxicity and can be used in combination together for maximum result. 

The anti-CXCR4 antibody ulocuplumab has exciting potential, says Ghobrial. The antibody has shown promising results in combination with lenalidomide (Revlimid) plus dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.

SELECTED
LANGUAGE


Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Antibodies offer limited toxicity and can be used in combination together for maximum result. 

The anti-CXCR4 antibody ulocuplumab has exciting potential, says Ghobrial. The antibody has shown promising results in combination with lenalidomide (Revlimid) plus dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x